-
HEALTHCARE RESOURCE UTILIZATION AND COSTS IN MYASTHENIA GRAVIS AND GENERALIZED MYASTHENIA GRAVIS IN FRANCE: RELIEF, A CLAIMS-BASED STUDY
Aug 11, 2026, 17:16 PM -
PATIENT DEMOGRAPHICS, TREATMENT, AND QUALITY OF LIFE IN MULTIPLE MYELOMA: A REAL-WORLD SURVEY IN EUROPE
Aug 11, 2026, 17:16 PM -
FROM SHARED EVIDENCE TO DIFFERENT RECOMMENDATIONS: A SYSTEMATIC REVIEW OF REVIEWS OF OSTEOPOROSIS SCREENING
Aug 11, 2026, 17:16 PM -
PLATINUM-BASED ADJUVANT CHEMOTHERAPY IN ELDERLY PATIENTS WITH RESECTED NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW AND META-ANALYSIS
Aug 11, 2026, 17:16 PM -
THE SOCIOECONOMIC CONSEQUENCES OF CANCER FOR PATIENTS - ACTIONS NEEDED AND FEASIBLE
Aug 11, 2026, 17:16 PM -
REIMBURSEMENT UNDER UNCERTAINTY: HOW EUROPEAN HTA ORGANISATIONS MANAGE EVIDENCE GAPS IN ONCOLOGY — A CASE STUDY OF PARP INHIBITORS
Aug 11, 2026, 17:16 PM -
ASSOCIATION BETWEEN EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY'S MAGNITUDE OF CLINICAL BENEFIT SCALE FOR HAEMATOLOGICAL MALIGNANCIES (ESMO-MCBS:H) AND SUBSIDY DECISIONS FOR THERAPIES IN SINGAPORE
Aug 11, 2026, 17:16 PM -
OBSERVED VERSUS FORECASTED UPTAKE OF NICE-RECOMMENDED OBESITY MEDICINES IN ENGLAND
Aug 11, 2026, 17:16 PM -
COST UTILITY ANALYSIS OF BUDESONIDE/GLYCOPYRROLATE/FORMOTEROL FUMARATE VERSUS FLUTICASONE FUROATE/UMECLIDINIUM/VILANTEROL FOR MODERATE TO VERY SEVERE COPD: A COLOMBIAN PAYER PERSPECTIVE
Aug 11, 2026, 17:16 PM -
ECONOMIC EVALUATION AND BUDGET IMPACT OF IMPLEMENTING TACE FOR HEPATOCELLULAR CARCINOMA IN BULGARIA
Aug 11, 2026, 17:16 PM -
REVIEW OF CLINICAL OUTCOME ASSESSMENTS (COA) IN DRUG APPROVALS 2024-25, INSIGHTS FROM FDA AND EMA LABELLING
Aug 11, 2026, 17:16 PM -
DISTINGUISHING VERIFICATION FROM JUDGMENT IN HUMAN-IN-THE-LOOP EVIDENCE SYNTHESIS
Aug 11, 2026, 17:16 PM -
FISCAL IMPACT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN THE UNITED STATES A GOVERNMENT EXPENDITURE PERSPECTIVE
Aug 11, 2026, 17:16 PM -
DOES EQ-HWB CAPTURE THE IMPACT OF CAREGIVING? A COMPARATIVE STUDY OF PERCEIVED COMPREHENSIVENESS AMONG CAREGIVERS AND NON-CAREGIVERS
Aug 11, 2026, 17:16 PM -
REAL WORLD SURVIVAL OUTCOMES FOLLOWING REIMBURSED ANTI-PD-1 IMMUNOTHERAPY FOR MELANOMA IN IRELAND A POPULATION-BASED NATIONAL CANCER REGISTRY STUDY
Aug 11, 2026, 17:16 PM -
CATEGORISATION AND PREVALENCE OF UNCERTAINTIES IN SERVICE DELIVERY AND IMPLEMENTATION COSTS IN NICE HEALTH TECHNOLOGY ASSESSMENT
Aug 11, 2026, 17:16 PM -
HEALTHCARE RESOURCE UTILIZATION ASSOCIATED WITH PEDIATRIC PNEUMOCOCCAL DISEASE HOSPITALIZATIONS IN SPAIN: RESULTS FROM THE NATIONAL HOSPITAL DISCHARGE DATABASE
Aug 11, 2026, 17:16 PM -
UNDERSTANDING THE ECONOMIC IMPACT OF SURGICAL TREATMENT PATHWAYS IN RECTAL CANCER
Aug 11, 2026, 17:16 PM -
A NEW VALUE SET, AN OLD QUESTION: DISEASE-SPECIFIC UTILITY MEASURES IN NICE TECHNOLOGY APPRAISALS AND THE IMPLICATIONS OF THE NEW UK EQ-5D-5L VALUE SET
Aug 11, 2026, 17:16 PM -
A MINIMUM PERFORMANCE-REPORTING STANDARD FOR AI IN SYSTEMATIC LITERATURE REVIEW IN ABSTRACTS PRESENTED IN ISPOR
Aug 11, 2026, 17:16 PM
